Historically, drugs that alter epigenetic marks, such as HDAC and DNA methyltransferase inhibitors, have been investigated as options to increase HbF levels, which effectively blocks hemoglobin S polymerization and ameliorate clinical symptoms of SCD [45]. The gene discussed is HDAC9; the disease is Schnyder corneal dystrophy.